Andrew Elliott Place, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 13 | 2024 | 1519 | 2.490 |
Why?
|
| Asparaginase | 7 | 2024 | 236 | 1.310 |
Why?
|
| Bacillus | 1 | 2018 | 77 | 0.650 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2023 | 407 | 0.620 |
Why?
|
| Cataract | 1 | 2022 | 834 | 0.530 |
Why?
|
| Polyethylene Glycols | 3 | 2021 | 1182 | 0.500 |
Why?
|
| Oleanolic Acid | 6 | 2005 | 43 | 0.490 |
Why?
|
| Hematologic Neoplasms | 2 | 2018 | 1832 | 0.490 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 1179 | 0.460 |
Why?
|
| Neutropenia | 1 | 2018 | 895 | 0.450 |
Why?
|
| Clinical Protocols | 1 | 2018 | 1462 | 0.410 |
Why?
|
| Bacteremia | 1 | 2018 | 962 | 0.410 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2024 | 11524 | 0.400 |
Why?
|
| Antineoplastic Agents | 8 | 2018 | 13695 | 0.350 |
Why?
|
| Escherichia coli Proteins | 1 | 2015 | 1050 | 0.330 |
Why?
|
| Sulfonamides | 1 | 2018 | 1938 | 0.320 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2018 | 222 | 0.310 |
Why?
|
| Neoplasm, Residual | 3 | 2022 | 973 | 0.310 |
Why?
|
| Lymphoma | 3 | 2023 | 1877 | 0.300 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2021 | 9239 | 0.270 |
Why?
|
| Child | 22 | 2024 | 77709 | 0.240 |
Why?
|
| Disease-Free Survival | 5 | 2023 | 6895 | 0.230 |
Why?
|
| Escherichia coli | 1 | 2015 | 4217 | 0.230 |
Why?
|
| Imidazoles | 3 | 2005 | 1206 | 0.220 |
Why?
|
| Infant | 11 | 2022 | 35136 | 0.210 |
Why?
|
| Adolescent | 16 | 2024 | 85781 | 0.210 |
Why?
|
| Child, Preschool | 12 | 2021 | 41006 | 0.200 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 5442 | 0.190 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2022 | 3523 | 0.190 |
Why?
|
| Hypertriglyceridemia | 1 | 2023 | 293 | 0.180 |
Why?
|
| Leukemia | 2 | 2021 | 1511 | 0.180 |
Why?
|
| Osteonecrosis | 1 | 2022 | 227 | 0.180 |
Why?
|
| Vancomycin Resistance | 1 | 2020 | 128 | 0.180 |
Why?
|
| Tumor Microenvironment | 1 | 2011 | 3586 | 0.170 |
Why?
|
| Remission Induction | 3 | 2020 | 2386 | 0.160 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2021 | 651 | 0.160 |
Why?
|
| Galectins | 1 | 2021 | 268 | 0.160 |
Why?
|
| Cholecalciferol | 1 | 2003 | 537 | 0.160 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2018 | 2109 | 0.160 |
Why?
|
| Immune Evasion | 1 | 2021 | 360 | 0.150 |
Why?
|
| Vancomycin | 1 | 2020 | 501 | 0.150 |
Why?
|
| Fibroblasts | 3 | 2016 | 4161 | 0.140 |
Why?
|
| Age Factors | 4 | 2018 | 18370 | 0.140 |
Why?
|
| Vincristine | 1 | 2018 | 1039 | 0.130 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 892 | 0.130 |
Why?
|
| Neoplasms | 4 | 2020 | 21683 | 0.130 |
Why?
|
| Tissue Banks | 1 | 2016 | 184 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2021 | 3557 | 0.130 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 426 | 0.120 |
Why?
|
| Injections, Intramuscular | 1 | 2015 | 552 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2016 | 538 | 0.110 |
Why?
|
| Purines | 1 | 2016 | 594 | 0.110 |
Why?
|
| Prednisone | 1 | 2018 | 1574 | 0.110 |
Why?
|
| Young Adult | 10 | 2024 | 56430 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 1 | 2021 | 1376 | 0.110 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2018 | 689 | 0.110 |
Why?
|
| Aminopyridines | 1 | 2016 | 542 | 0.110 |
Why?
|
| Orthopedics | 1 | 2022 | 904 | 0.110 |
Why?
|
| Humans | 36 | 2024 | 744343 | 0.110 |
Why?
|
| Prognosis | 5 | 2022 | 29063 | 0.110 |
Why?
|
| Triterpenes | 2 | 2003 | 80 | 0.100 |
Why?
|
| Doxorubicin | 1 | 2018 | 2234 | 0.100 |
Why?
|
| Treatment Outcome | 6 | 2022 | 63114 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2018 | 10943 | 0.090 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 2183 | 0.090 |
Why?
|
| U937 Cells | 4 | 2005 | 268 | 0.090 |
Why?
|
| Canada | 1 | 2015 | 2065 | 0.090 |
Why?
|
| Gene Expression Profiling | 3 | 2016 | 9438 | 0.090 |
Why?
|
| Matrix Metalloproteinases | 1 | 2011 | 391 | 0.080 |
Why?
|
| Quality of Life | 2 | 2023 | 12804 | 0.080 |
Why?
|
| Breast Neoplasms | 2 | 2016 | 20822 | 0.080 |
Why?
|
| Male | 14 | 2022 | 350118 | 0.080 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 494 | 0.080 |
Why?
|
| Retrospective Studies | 6 | 2023 | 77449 | 0.080 |
Why?
|
| Female | 16 | 2022 | 380194 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2021 | 5172 | 0.070 |
Why?
|
| Research Design | 3 | 2018 | 5987 | 0.070 |
Why?
|
| Nitric Oxide Synthase Type II | 3 | 2003 | 534 | 0.070 |
Why?
|
| Recurrence | 1 | 2018 | 8340 | 0.070 |
Why?
|
| Adult | 9 | 2023 | 214055 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2022 | 12354 | 0.070 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2020 | 841 | 0.070 |
Why?
|
| Nitric Oxide Synthase | 3 | 2003 | 916 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 6538 | 0.060 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2005 | 171 | 0.060 |
Why?
|
| Incidence | 2 | 2022 | 20947 | 0.060 |
Why?
|
| Trans-Activators | 2 | 2005 | 2924 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 1999 | 1285 | 0.060 |
Why?
|
| Leukocytes | 1 | 2011 | 2043 | 0.060 |
Why?
|
| Terpenes | 1 | 2003 | 98 | 0.060 |
Why?
|
| Methyl Methanesulfonate | 2 | 1999 | 27 | 0.050 |
Why?
|
| Cytarabine | 2 | 2022 | 692 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2003 | 459 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 7181 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 5535 | 0.050 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2023 | 379 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2013 | 2265 | 0.050 |
Why?
|
| Models, Chemical | 1 | 2003 | 626 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 4851 | 0.050 |
Why?
|
| Disease Progression | 2 | 2021 | 13284 | 0.050 |
Why?
|
| Cell Line, Tumor | 4 | 2016 | 16689 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 1999 | 2455 | 0.040 |
Why?
|
| T-Lymphocytes | 3 | 2023 | 10180 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2011 | 3690 | 0.040 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2021 | 345 | 0.040 |
Why?
|
| Time Factors | 2 | 2015 | 40075 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 871 | 0.040 |
Why?
|
| Cell Division | 2 | 2003 | 4568 | 0.040 |
Why?
|
| Pediatrics | 1 | 2013 | 3475 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2020 | 9959 | 0.040 |
Why?
|
| Cell Separation | 1 | 2003 | 1751 | 0.040 |
Why?
|
| Germ Cells | 1 | 2021 | 631 | 0.040 |
Why?
|
| Animals | 10 | 2023 | 168757 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 2 | 2021 | 2727 | 0.040 |
Why?
|
| Drug Synergism | 2 | 2016 | 1792 | 0.040 |
Why?
|
| Ikaros Transcription Factor | 1 | 2018 | 217 | 0.040 |
Why?
|
| Genomics | 1 | 2013 | 5720 | 0.040 |
Why?
|
| Nitriles | 1 | 2002 | 956 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2003 | 1783 | 0.040 |
Why?
|
| Mice | 8 | 2023 | 81183 | 0.040 |
Why?
|
| Caspases | 1 | 2000 | 928 | 0.040 |
Why?
|
| Leukemia, Myeloid | 1 | 2000 | 707 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2018 | 23338 | 0.040 |
Why?
|
| DNA-Binding Proteins | 2 | 2005 | 9648 | 0.040 |
Why?
|
| Survival Rate | 2 | 2021 | 12788 | 0.040 |
Why?
|
| B-Lymphocytes | 2 | 2021 | 4665 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 1999 | 648 | 0.030 |
Why?
|
| Azacitidine | 1 | 2018 | 347 | 0.030 |
Why?
|
| Fatigue | 1 | 2023 | 1531 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2023 | 1660 | 0.030 |
Why?
|
| Leukemia, Experimental | 1 | 2016 | 246 | 0.030 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2018 | 294 | 0.030 |
Why?
|
| United States | 3 | 2021 | 69872 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2000 | 1434 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 39050 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2003 | 2007 | 0.030 |
Why?
|
| Isoquinolines | 1 | 2016 | 367 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2018 | 1588 | 0.030 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2018 | 670 | 0.030 |
Why?
|
| Dexamethasone | 2 | 2016 | 1951 | 0.030 |
Why?
|
| Monocytes | 1 | 2003 | 2596 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2016 | 755 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 380 | 0.030 |
Why?
|
| Mutation | 3 | 2023 | 29786 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 1677 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2002 | 2132 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 6314 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2003 | 5974 | 0.030 |
Why?
|
| Risk Factors | 2 | 2018 | 72290 | 0.030 |
Why?
|
| Overweight | 1 | 2023 | 2371 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 2085 | 0.030 |
Why?
|
| Viral Proteins | 1 | 1999 | 1900 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 1878 | 0.020 |
Why?
|
| Random Allocation | 1 | 2016 | 2429 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2018 | 1275 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2021 | 5078 | 0.020 |
Why?
|
| Macrophages | 2 | 2003 | 5655 | 0.020 |
Why?
|
| Cell Differentiation | 3 | 2003 | 11483 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2018 | 3913 | 0.020 |
Why?
|
| Focal Adhesion Kinase 2 | 2 | 1999 | 86 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1999 | 2282 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 3597 | 0.020 |
Why?
|
| Pain | 1 | 2023 | 4986 | 0.020 |
Why?
|
| bcl-X Protein | 2 | 2000 | 411 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2018 | 2948 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2016 | 2504 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2003 | 12208 | 0.020 |
Why?
|
| Proteome | 1 | 2016 | 1799 | 0.020 |
Why?
|
| Phosphorylation | 3 | 2005 | 8436 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2023 | 12720 | 0.020 |
Why?
|
| Piperazines | 1 | 2016 | 2488 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2018 | 10252 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2021 | 53288 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2005 | 475 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 12245 | 0.020 |
Why?
|
| Transfection | 2 | 2005 | 5892 | 0.020 |
Why?
|
| Isoenzymes | 2 | 1999 | 1726 | 0.010 |
Why?
|
| Forecasting | 1 | 2013 | 2951 | 0.010 |
Why?
|
| Apoptosis | 1 | 2000 | 9727 | 0.010 |
Why?
|
| Response Elements | 1 | 2005 | 312 | 0.010 |
Why?
|
| Internet | 1 | 2016 | 3064 | 0.010 |
Why?
|
| Mink | 1 | 2003 | 44 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 3703 | 0.010 |
Why?
|
| Inflammation | 1 | 2003 | 10638 | 0.010 |
Why?
|
| Smad7 Protein | 1 | 2003 | 41 | 0.010 |
Why?
|
| Enzyme Activation | 2 | 1999 | 3701 | 0.010 |
Why?
|
| Smad2 Protein | 1 | 2003 | 156 | 0.010 |
Why?
|
| Heme Oxygenase-1 | 1 | 2005 | 381 | 0.010 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2005 | 514 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 2 | 2005 | 5867 | 0.010 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2005 | 377 | 0.010 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2003 | 147 | 0.010 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2003 | 281 | 0.010 |
Why?
|
| Acetyltransferases | 1 | 2003 | 234 | 0.010 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2003 | 314 | 0.010 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2003 | 236 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2005 | 1472 | 0.010 |
Why?
|
| Obesity | 1 | 2023 | 12745 | 0.010 |
Why?
|
| Histone Acetyltransferases | 1 | 2003 | 336 | 0.010 |
Why?
|
| Caspase 9 | 1 | 2000 | 188 | 0.010 |
Why?
|
| Aged | 2 | 2023 | 163280 | 0.010 |
Why?
|
| Caspase 8 | 1 | 2000 | 195 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2000 | 242 | 0.010 |
Why?
|
| MAP Kinase Kinase 3 | 1 | 1999 | 25 | 0.010 |
Why?
|
| MAP Kinase Kinase 6 | 1 | 1999 | 25 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 2000 | 365 | 0.010 |
Why?
|
| Vanadates | 1 | 1999 | 82 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2003 | 644 | 0.010 |
Why?
|
| PC12 Cells | 1 | 1999 | 330 | 0.010 |
Why?
|
| Signal Transduction | 4 | 2005 | 23403 | 0.010 |
Why?
|
| Protein Kinase C-delta | 1 | 1999 | 123 | 0.010 |
Why?
|
| Phenotype | 1 | 2016 | 16365 | 0.010 |
Why?
|
| Phosphotyrosine | 1 | 1999 | 457 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2021 | 40561 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1999 | 683 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 1999 | 329 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2000 | 758 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2002 | 1899 | 0.010 |
Why?
|
| Middle Aged | 2 | 2022 | 213383 | 0.010 |
Why?
|
| Serpins | 1 | 1999 | 247 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1999 | 1101 | 0.010 |
Why?
|
| Antioxidants | 1 | 2005 | 1663 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 7913 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 1999 | 452 | 0.010 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 1999 | 440 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 1999 | 473 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2000 | 640 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2002 | 3129 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 1999 | 611 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 1999 | 697 | 0.010 |
Why?
|
| Membrane Proteins | 2 | 2005 | 7880 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 1999 | 1227 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 1999 | 1060 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2005 | 3086 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2002 | 3206 | 0.010 |
Why?
|
| Cisplatin | 1 | 1999 | 1662 | 0.010 |
Why?
|
| Rats | 2 | 1999 | 24260 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2003 | 3462 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 1999 | 1403 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 13033 | 0.000 |
Why?
|
| Cell Line | 1 | 1999 | 15997 | 0.000 |
Why?
|
| Lung | 1 | 2003 | 9856 | 0.000 |
Why?
|